Ventyx Biosciences

Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M
Fierce Biotech
Mon, 09/23/24 - 11:33 am
Sanofi
Ventyx Biosciences
obesity
Parkinson's Disease
Ventyx Ends Development of TYK2 Inhibitor After Phase II Flop in Crohn’s Disease
BioSpace
Tue, 07/30/24 - 11:34 am
Ventyx Biosciences
VTX958
Crohn's Disease
Even with phase 2 success, Ventyx halts TYK2 inhibitor, sending stock plummeting 70%
Fierce Biotech
Tue, 11/7/23 - 10:00 am
Ventyx Biosciences
clinical trials
TYK2 inhibitors
VTX958
psoriasis
Ventyx Biosciences reports data from ulcerative colitis drug trial
Clinical Trials Arena
Tue, 10/10/23 - 10:08 am
Ventyx Biosciences
ulcerative colitis
VTX002
clinical trials
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
Thu, 06/15/23 - 09:54 am
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
Ventyx touts early data for potential rival to Bristol Myers psoriasis drug
BioPharma Dive
Tue, 08/16/22 - 12:22 pm
Ventyx Biosciences
clinical trials
Bristol Myers Squibb
psoriasis
VTX958
deucravacitinib
Ventyx nabs a $152M upsized IPO to challenge BMS' Zeposia—and a backer with intimate knowledge of its rival
Fierce Biotech
Fri, 10/22/21 - 12:04 pm
Ventyx Biosciences
IPOs
autoimmune disease
Bristol Myers Squibb
Zeposia
Ventyx bags $114M to test drugs against hot immunology targets
Fierce Biotech
Tue, 03/9/21 - 10:42 am
Ventyx Biosciences
funding
IBD